Natera Inc NTRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
-
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
-
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
-
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
-
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
-
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
-
Natera Reports Second Quarter 2026 Financial Results
-
Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Trading Information
- Previous Close Price
- $408.47
- Day Range
- $401.00–413.36
- 52-Week Range
- $157.43–427.47
- Bid/Ask
- $409.69 / $413.87
- Shares Outstanding
- 144.14M
- Market Cap
- $59.15B
- Volume/Avg
- 2M / 1M
Key Statistics
- Price/Earnings (Normalized)
- 566.28
- Price/Sales
- 21.14
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 6,140
- Website
- https://www.natera.com
Valuation
|
Metric
|
NTRA
|
|---|---|
Price/Earnings (Normalized) | 566.28 |
Price/Book Value | 32.20 |
Price/Sales | 21.14 |
Price/Cash Flow | 205.06 |
Price/Earnings
NTRA
Financial Strength
|
Metric
|
NTRA
|
|---|---|
Quick Ratio | 2.74 |
Current Ratio | 3.00 |
Interest Coverage | −75.87 |
Quick Ratio
NTRA
Profitability
|
Metric
|
NTRA
|
|---|---|
Return on Assets (Normalized) | 4.35% |
Return on Equity (Normalized) | 6.27% |
Return on Invested Capital (Normalized) | 3.92% |
Return on Assets
NTRA
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|VV!WTzd | LOCK|<q | $242B | |||
| Danaher Corp
DHR
| LOCK|T?l&Z?? | LOCK|#L> | $150B | |||
| Agilent Technologies Inc
A
| LOCK|LD!g!YF | LOCK|?<Q | $47B | |||
| IQVIA Holdings Inc
IQV
| LOCK|p?^g&> | LOCK|@J%c! | $43B | |||
| Waters Corp
WAT
| LOCK|hGL>QKT | LOCK|C>@ | $42B | |||
| Illumina Inc
ILMN
| LOCK|Qv#!?? | LOCK|qYTNz | $41B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|$XmRhf? | LOCK|hJ | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|B!!>!P# | LOCK|v&z>S | $30B | |||
| Quest Diagnostics Inc
DGX
| LOCK|Q!#%&PT | LOCK|%ZSw# | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|GByl^BM | LOCK|Tlhlr | $25B |
United States